CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $203.94M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 14.55: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
283.03BKRW203.94M · vs all stocks (USD)
Revenue (TTM)
16.82BKRW12.12M · vs all stocks (USD)
Profit Margin
-0.22%vs Biotechnology peers
52-Week Change
-44.26%vs all stocks
Market Capitalization
283.03BKRW203.94M · vs all stocks (USD)
Enterprise Value
251.52BKRW181.24M · vs all stocks (USD)
Forward P/E
61.94xvs Biotechnology peers
Price to Sales (TTM)
16.14xvs Biotechnology peers
Price to Book (MRQ)
5.78xvs Biotechnology peers
Enterprise to Revenue
14.95xvs Biotechnology peers
Gross Margin
67.30%vs Biotechnology peers
Profit Margin
-0.22%vs Biotechnology peers
Operating Margin
-28.91%vs Biotechnology peers
Return on Assets (TTM)
-1.31%vs Biotechnology peers
Return on Equity (TTM)
-0.08%vs Biotechnology peers
Revenue (TTM)
16.82BKRW12.12M · vs all stocks (USD)
Revenue per Share (TTM)
2.06KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
9.20%vs Biotechnology peers
Gross Profit (TTM)
11.79BKRW8.50M · vs all stocks (USD)
EBITDA (TTM)
653.23MKRW470.69K · vs all stocks (USD)
Net Income (TTM)
-36.35MKRW-26.20K · vs all stocks (USD)
Operating Cash Flow (TTM)
358.20MKRW258.11K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.21BKRW-3.75M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
16.48BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
4.95BKRWFY2025 · Dec 31, 2025Gross Profit
11.53BKRWFY2025 · Dec 31, 2025Operating Income
-719.54MKRW-518.47K · vs all stocks (USD)
Pre-tax Income
-311.08MKRWFY2025 · Dec 31, 2025Net Income
-311.08MKRWFY2025 · Dec 31, 2025EBIT
56.22MKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
653.23MKRWFY2025 · Dec 31, 2025Research & Development
7.58BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.60BKRWFY2025 · Dec 31, 2025Other Operating Expenses
105.24MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
926.51MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
367.31MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-311.08MKRWFY2025 · Dec 31, 2025Operating Cash Flow
-262.53MKRWFY2025 · Dec 31, 2025Free Cash Flow
-3.39BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.79BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-311.08MKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.19BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-559.21MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-435.76MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-144.01MKRWFY2025 · Dec 31, 2025Capital Expenditures
-3.13BKRWFY2025 · Dec 31, 2025Purchase of Investments
-89.78BKRWFY2025 · Dec 31, 2025Sale of Investments
95.02BKRWFY2025 · Dec 31, 2025Other Investing Activity
-427.32MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
1.68BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
1.08BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-4.38BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.38BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.44BKRWFY2025 · Dec 31, 2025Shares Outstanding
8.20MSharesUpdated Aug 20, 2026Float Shares
5.61MSharesUpdated Aug 20, 2026% Held by Insiders
30.08%vs all stocks
% Held by Institutions
6.16%vs all stocks
Total Cash (MRQ)
33.60BKRW24.21M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.10KKRWUpdated Aug 20, 2026Total Debt (MRQ)
7.43BKRW5.35M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1517xvs Biotechnology peers
Current Ratio (MRQ)
5.11xvs Biotechnology peers
Book Value per Share (MRQ)
5.96KKRWUpdated Aug 20, 2026Total Assets
59.27BKRW42.70M · vs all stocks (USD)
Total Current Assets
43.27BKRWFY2025 · Dec 31, 2025Total Liabilities
11.16BKRWFY2025 · Dec 31, 2025Total Non-current Assets
16.00BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
3.11BKRWFY2025 · Dec 31, 2025Total Current Liabilities
8.04BKRWFY2025 · Dec 31, 2025Cash
284.00KKRWFY2025 · Dec 31, 2025Cash Equivalents
6.79BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.79BKRWFY2025 · Dec 31, 2025Other Short-term Investments
30.21BKRWFY2025 · Dec 31, 2025Accounts Receivable
2.24BKRWFY2025 · Dec 31, 2025Inventory
3.04BKRWFY2025 · Dec 31, 2025Accounts Payable
47.69MKRWFY2025 · Dec 31, 2025Short-term Debt
6.69BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-1.20KKRWFY2025 · Dec 31, 2025Long-term Debt
1.02BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-170.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
4.10BKRWFY2025 · Dec 31, 2025Retained Earnings
-70.60BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
48.11BKRW34.66M · vs all stocks (USD)
52-Week Low
30.15KKRWUpdated Aug 20, 202652-Week High
101.00KKRWUpdated Aug 20, 202652-Week Change
-44.26%vs all stocks
50-Day MA
38.63KKRWUpdated Aug 20, 2026200-Day MA
62.76KKRWUpdated Aug 20, 2026Avg 10-Day Volume
33.58KSharesUpdated Aug 20, 2026Avg 30-Day Volume
38.47KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-38.00KRWUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.14Revenue Growth YoY: 0.09
High gross margins eroded by operating costsNotable
Gross Margin: 0.67Profit Margin: -0.00
Financial Health
Altman Z-Score 14.55: safe zoneNotable
Altman Z-Score: 14.55
High structural barrier to entryNotable
Barrier to Entry: 3.35
Consistent revenue growth patternNotable
Growth Consistency Score: 0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $203.94M, lower than 95% of all stocks globallySignificant
Market cap (USD): 203,943,027.318Global P5: 269,387,740.27
Revenue is $12.12M, lower than 95% of all stocks globallySignificant
Revenue (USD): 12,123,155.589Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ch. Karnchang Public Company Limited
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthRevenue Growing With Receivables Growing
Aurinia Pharmaceuticals Inc.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthRevenue Growing With Receivables Growing
Coforge Limited
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthRevenue Growing With Receivables Growing